S ignificant progress in the treatment of moderate to severe psoriasis with biologic therapy has been made in recent years. Certain body regions, however, including the scalp, palms and/or soles, and nails, remain challenging to treat. These areas are commonly affected in psoriasis, with reported scalp psoriasis involvement in 50% to 80% of patients and nail psoriasis involvement in 10% to 50% of patients, with higher numbers in those with psoriatic arthritis or more severe disease. [1] [2] [3] Estimates vary from 3% to 41% of patients with involvement of the palms and/or soles. 4 Of note, disease in these areas is associated with greater disability and reduced quality of life. 2, [5] [6] [7] Multiple therapies, including topical agents, phototherapy, traditional systemic agents, and biologic therapies, have had variable success in treating these regional forms of psoriasis. 1, 2, 8, 9 Data from larger controlled studies, which have been limited until recently, suggest that the results for biologic agents are more promising.
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The significantly better efficacy of guselkumab, an interleukin 23 inhibitor (Janssen Research & Development, LLC), compared with placebo and adalimumab as well as a reassuring safety profile for guselkumab were reported in 2 pivotal, phase 3 trials (VOYAGE 1 and VOYAGE 2). 11, 12 In this article, we present pooled efficacy data for regional psoriasis end points initially reported in these studies, which are derived from one of the largest clinical trial databases for psoriasis. In addition, complete clearance of disease that involves the scalp, nails, and palms and/ or soles as well as the correlation between regional disease end points and patient-reported outcomes were assessed.
Methods

Patients and Study Design
Detailed methods and patient characteristics for the VOYAGE 1 and VOYAGE 2 studies have been reported previously. 11, 12 Patient inclusion and exclusion criteria were identical for both studies. Eligible patients (≥18 years of age) had a diagnosis of plaque-type psoriasis for at least 6 months before the first administration of study agent, a baseline Psoriasis Area and Severity Index (PASI) score (range of 0-72, with lower scores indicating less severe disease) of at least 12, an Investigator's Global Assessment (IGA) score (range of 0-4, with 0 indicating cleared and 4 indicating severe) of at least 3, and at least 10% body surface area involved with psoriasis; they also had to be candidates for phototherapy or systemic psoriasis treatments. The studies were conducted from November 3, 2014 , to May 19, 2016 and 115 (VOYAGE 2) global sites. This post hoc data analysis was performed from February 10, 2017, through November 15, 2017. For the PASI or IGA end points, the original analyses were intention to treat; however, for regional psoriasis, the intent was to focus on only patients with minimal regional diseases. The study protocols were approved by multiple institutional review boards or ethics committees (eg, Sterling Institutional Review Board), and all patients provided written informed consent before study procedures were initiated. These studies were conducted in accordance with current International Committee on Harmonization guidelines on Good Clinical Practice 16 and applicable regulatory and countryspecific requirements.
Both VOYAGE 1 and VOYAGE 2 were phase 3, multicenter, randomized, double-blind, placebo-and adalimumab-controlled studies. The study designs were identical through week 24. Patients were randomized using a permuted block method at baseline to receive guselkumab, 100 mg, at weeks 0, 4, 12, and 20; placebo at weeks 0, 4, and 12 followed by guselkumab, 100 mg, at weeks 16 and 20; or adalimumab, 80 mg, at week 0, 40 mg at week 1, and 40 mg every 2 weeks through week 23. Overall, 837 patients (329 in the guselkumab group, 334 in the adalimumab group, and 174 in the placebo group) were randomized in VOYAGE 1 and 992 (496 in the guselkumab group, 248 in the adalimumab group, and 248 in the placebo group) in VOYAGE 2. Detailed study designs through week 48 of both trials have been reported previously.
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Efficacy Assessments
Regional efficacy was assessed through week 24 using pooled data from VOYAGE 1 and VOYAGE 2. Scalp psoriasis was graded using the scalp-specific IGA (ss-IGA), which assesses lesions for degree of redness, thickness, and scaling on a 5-point scale, with 0 indicating absence of disease and 4 indicating severe disease (eTable 1 in the Supplement). Psoriasis on the palms and/or soles was evaluated using the Physician's Global Assessment of the hands and/or feet (hf-PGA); severity of plaques on the palms and/ or soles was also scored on a 5-point scale, with 0 indicating clear and 4 indicating severe (eTable 2 in the Supplement). Fingernail involvement with psoriasis was evaluated using the fingernail PGA (f-PGA), with rating of the overall condition of the fingernails also based on a 5-point scale, with 0 indicating clear and 4 indicating severe (eTable 3 in the Supplement). Fingernail psoriasis was also assessed using the target Nail Psoriasis Severity Index (NAPSI), in which the nail most affected by psoriasis (target nail) is divided into quadrants and graded for psoriasis of the nail matrix (pitting, leukonychia, red spots in the lunula, and nail plate crumbling) and nail bed (onycholysis, splinter hemorrhages, oil drop discoloration, and nail bed hyperkeratosis) on a scale of 0 to 4 for a total score ranging from 0 to 8; a higher score indicates more severe disease (eTable 4 in the Supplement).
17 Patientreported outcomes were assessed using the Dermatology Life Quality Index (DLQI); a score of 0 or 1 indicates no effect of psoriasis or its treatment on health-related quality of life (HRQoL).
Statistical Analysis
Regional psoriasis scores were analyzed for patients with ss-IGA, f-PGA, and hf-PGA scores of 2 or more (mild or worse disease) at baseline. End points included the proportion of patients achieving clear or near-clear status (scores of 0 or 1) for the ss-IGA (absent or very mild scalp psoriasis), the hf-PGA (clear or almost clear psoriasis of the palms and/or soles), and the f-PGA (clear or minimal fingernail psoriasis) as well as the mean percentage of improvement in target NAPSI scores at weeks 16 and 24. Responders also had to achieve at least a 2-grade improvement from baseline in ss-IGA and hf-PGA scores. Complete clearance was assessed on the basis of the proportion of patients with a score of 0 for the ss-IGA, f-PGA, and hf-PGA and target NAPSI (100% improvement) at the same time points. Binary end points were analyzed using a Cochran-Mantel-Haenszel χ 2 test stratified by study and investigator site, and continuous end points were analyzed using an analysis of variance model with study and investigator site as covariates. All statistical testing was performed using 2-sided analyses (α = .05). These analyses of pooled data were not multiplicity controlled, and all reported P values are nominal. Patients were considered to be nonresponders (binary end points) or had baseline values carried forward (continuous end points) if they had discontinued study treatment because of a lack of efficacy or an adverse event of worsening of psoriasis or if they had started a protocol-prohibited treatment that could improve psoriasis. Patients with missing data were treated similarly for binary variables, and the last observation was carried forward for continuous variables. A post hoc analysis was performed to evaluate the effect of improvement in regional disease on patients' ability to achieve a DLQI score of 0 or 1 (no effect of psoriasis on HRQoL) at week 24 while adjusting for overall skin improvement across the entire body. A multiple logistic regression model using data from patients in the guselkumab and adalimumab treatment groups was used to test variables potentially associated with achieving a DLQI score of 0 or 1. ) had a baseline score of 2 or higher on the ss-IGA, with 461 (25.2%) on the hf-PGA, and 928 (50.7%) on the f-PGA; all were included in the current analysis ( Figure 1 ). Most patients in the active treatment groups (range, 92.5%-96.6%) completed the study agent through week 24 ( Figure 1 ). Regional baseline psoriasis characteristics for the overall population were generally comparable across treatment groups ( Table 1 ) and were consistent with those observed among patients with scalp, nail, and palm and/or sole psoriasis (eTables 5-8 in the Supplement).
Scalp Psoriasis
The number of patients achieving absent or very mild scalp psoriasis (ss-IGA score of 0 or 1) with at least a 2-grade improvement from baseline in the guselkumab group was statistically significantly higher compared with that in the placebo group ( (Figure 2 ). (Figure 2 ).
Psoriasis of the Palms and/or Soles
Fingernail Psoriasis
The number of patients achieving cleared or minimal fingernail psoriasis (f-PGA score of 0 or 1) was statistically significantly higher in the guselkumab group vs the placebo group at week 16 (196 [46.7%] (Figure 2) . Similarly, improvements in target NAPSI score were statistically significantly greater for the guselkumab group vs the placebo group at week 16 (mean improvement, 37.5% vs 0.7%; P < .001) and comparable between the guselkumab and adalimumab groups at week 24 (52.9% vs 51.2%, P = .96) ( 
Patient flow for the entire VOYAGE 1 and VOYAGE 2 populations have been reported previously. 11,12 ADA indicates adalimumab; AE, adverse event; DC, discontinued; f-PGA, fingernail Physician's Global Assessment; GUS, guselkumab; hf-PGA, Physician's Global Assessment of the hands and/or feet; LOE, lack of efficacy; LTF, lost to follow-up; NC, noncompliance with treatment; PBO, placebo; PV, protocol violation; ss-IGA, scalp-specific Investigator's Global Assessment; WD, withdrawal by patient. a To be eligible for these analyses, patients had to have a baseline score of 2 or higher. 
Association of Regional Disease Response and HRQoL Improvements
Logistic regression modeling showed that, among patients in the guselkumab and adalimumab treatment groups, the following factors were identified as indicators for achieving a DLQI score of 0 or 1 (no effect of psoriasis on HRQoL) at week 24: overall PASI response at week 24 (OR, 0.786; 95% CI, 0.721-0.858; P < .001), overall IGA response at week 24 (OR, 0.683; 95% CI, 0.548-0.850; P < .001), and ss-IGA response at week 24 (OR, 0.780; 95% CI, 0.652-0.932; P = .006). Conversely, treatment group and hf-PGA and f-PGA scores did not meet the significance level of 0.10 required for inclusion in the model.
Safety
Safety data were not analyzed separately for the regional disease populations studied here. However, on the basis of the results from the overall study populations in the VOYAGE 1 and VOYAGE 2 studies, common adverse events occurred in similar proportions among patients in each active treatment group. Serious adverse events and discontinuations attributable to adverse events occurred infrequently. Detailed descriptions of the safety data from each study have been previously published.
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Discussion
In pooled analyses of prospectively defined regional psoriasis end points from the pivotal phase 3 studies (VOYAGE 1 and VOYAGE 2), we found that guselkumab was highly effective in treating the scalp, palms and/or soles, and fingernails. These combined trials comprise one of the largest clinical trial databases to date to evaluate regional psoriasis (>1800 patients) and include a comparator agent, adalimumab. Detailed assessments of regional forms of psoriasis were used to compare the efficacy of guselkumab with placebo and adalimumab. Guselkumab was superior to placebo with regard to the proportions of patients achieving near-complete and complete clearance of psoriasis of the scalp, palms and/or soles, and Compared with adalimumab at 6 months, statistically significantly greater improvements were observed with guselkumab for near-complete and complete clearance of psoriasis of the scalp and palms and/or soles as well as complete clearance in these regions. Responses were comparable between the active treatment groups based on 2 measures of fingernail psoriasis (f-PGA and target NAPSI). Because nail psoriasis responds more slowly than skin disease and complete nail replacement is protracted, 6 months may be insufficient to assess the ultimate effect of treatment on nail psoriasis.
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Reported prevalence rates of regional psoriasis have been variable. Data from historical estimates or clinical trials suggest that rates of involvement among patients with psoriasis vary from 50% to 80% for the scalp and 3% to 41% for the palms and/or soles. [1] [2] [3] [4] 21, 22 Nail psoriasis has been reported in 10% to 50% of patients, 3, 19, 23 with more consistent rates of 60% to 82% observed in recent clinical studies. 13, 15, [24] [25] [26] [27] In VOYAGE 1 and 2, more than 85% of patients had scalp psoriasis, less than 30% had psoriasis of the palms and/or soles, and nearly 60% had fingernail psoriasis; these rates are comparable to those reported in other clinical studies of patients with moderate to severe psoriasis, indicating that psoriasis in these areas is common. Although we collected data regarding any involvement of these regions in all enrolled patients, only those with at least mild disease were analyzed to ensure that measurable changes could be evaluated. Guselkumab was highly effective in treating psoriasis in the studied areas, particularly the scalp and palms and/or soles, with complete clearance achieved in approximately 70% of patients. Furthermore, guselkumab achieved responses superior to adalimumab, a commonly prescribed anti-tumor necrosis factor α antibody. Although multiple reports 9, 10, [13] [14] [15] 22, [24] [25] [26] [27] [28] [29] on treatment of the scalp, palms and/or soles, and nails have been published, results are difficult to compare across studies because of differences in study designs and patient characteristics. Although patient populations are well described and assessment tools are standardized for moderate to severe skin psoriasis in general, it is particularly challenging to compare results of regional psoriasis studies because they are highly variable for psoriasis of the scalp, palms and/or soles, and nails. Thus, the strengths of the data from VOYAGE 1 and VOYAGE 2 reported here, which can be used as a benchmark for future studies on this topic, derive from the use of the following: (1) a large standardized population with moderate to severe psoriatic disease, (2) the commonly used tools for assessment of regional psoriasis, and (3) an active comparator study design. Our findings also indicate that improvements in scalp psoriasis were associated with improvements in patient-reported HRQoL outcomes after adjusting for overall psoriasis across the entire body (IGA and PASI) . This association between greater improvements in HRQoL (ie, DLQI score of 0 or 1, indicating no effect of psoriasis on HRQoL) and clinical responses in scalp psoriasis (ss-IGA) may be attributable to the high visibility and consequent psychosocial effect of scalp lesions. Of interest, improve- ments in hand, foot, and fingernail psoriasis (as measured by hf-PGA and f-PGA) were not identified as indicators of improvements in HRQoL outcomes. However, the DLQI used to measure changes in HRQoL in these studies is not psoriasis specific and, thus, is not necessarily designed to evaluate psoriasis in these particular body regions.
Limitations
Some limitations of this study should be noted. VOYAGE 1 and 2 included only patients with moderate to severe psoriasis, and responses may vary in patients with mild psoriasis. In addition, these data are limited to the 24 weeks during which the study designs were identical.
Conclusions
In a large, pooled psoriasis data set from the VOYAGE 1 and 2 studies, we found that guselkumab was effective in treating regional psoriasis of the scalp, palms and/or soles, and fingernails. Guselkumab was superior to adalimumab for the treatment of psoriasis of the scalp and palms and/or soles and comparable to adalimumab for the fingernails. Because these body areas are commonly involved in patients with moderate to severe psoriasis, dermatologists should consider these results when making future treatment decisions. 
NOTABLE NOTES
Island Pedicle Flap-Its Place in History
Pooja Reddy, BA; Quynh-Giao Nguyen, MD; Ikue Shimizu, MD
The island pedicle flap, also known as the V-to-Y advancement flap, is highly regarded by reconstructive surgeons owing to its robust blood supply, color and textural match, minimization of tension, and inherent adaptability. Although used by dermatologists in contemporary practice, particularly for defects on the nose and central face, the V-to-Y flap's origins and historical contextualization are not as well known. Flap surgery was first described around 600 to 700 BC by Indian surgeon Susrata in his text Samahita and was mostly performed by the brick maker caste in India, who guarded the technique as a family secret. This medical knowledge was later shared with the Greeks and Romans.
1,2 After the Arabs occupied Sicily during the 9th to 12th centuries, the original Indian texts, translated to Arabic, were disseminated to all of Europe, historically among the first international trade of technical knowledge.
2
During the Middle Ages, there was a hiatus in flap surgery in Europe owing to the Catholic Church's condemnation of surgical practices; 2 centuries passed before the reintroduction of skin grafts and flaps in Europe.
The person at the nidus, British Army surgeon Cully Lyon Lucas, ironically found himself where flap surgery originated-India. Lucas wrote a letter, later read by surgeon Joseph Carpue, describing how an Indian bullock driver had his nose reconstructed via a forehead flap by a member of the brick maker caste.
2 After using the technique on 2 British army soldiers, Carpue published an article in 1816 that renewed interest in flap surgery.
The Industrial Revolution and World Wars further spurred innovation in the field of surgery, from the discovery of anesthesia to the use of aseptic techniques.
1,2 It was during this period of innovation that the V-to-Y flap was discovered. Originally credited to Ernst Blasius (1802-1875), the term island pedicle flap was coined by Johannes Esser in 1917. 3 Esser, a Dutch surgeon during World War I, described the use of "islands" of skin with named "pedicles" to treat wounded soldiers in Austria. 1, 3 In 1965, Barron and Emmett would demonstrate that the flap did not require one of the few named facial arteries, thereby greatly expanding its usefulness. The target nail is graded for nail matrix psoriasis and nail bed psoriasis in each quadrant, as described below: 
